Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

Nanorobots Designed for Drug Delivery

By BiotechDaily International staff writers
Posted on 16 Dec 2013
Image: The figure shows a nanocage in which eight unique DNA molecules are mixed together. The nanocage has four functional elements that transform themselves in response to changes in the surrounding temperature. These transformations either close (1A) or open (1B) the nanocage. By exploiting the temperature changes in the surroundings, the researchers trapped an active enzyme called horseradish peroxidase (HRP) in the nanocage (1C) (Photo courtesy of Sissel Juul).
Image: The figure shows a nanocage in which eight unique DNA molecules are mixed together. The nanocage has four functional elements that transform themselves in response to changes in the surrounding temperature. These transformations either close (1A) or open (1B) the nanocage. By exploiting the temperature changes in the surroundings, the researchers trapped an active enzyme called horseradish peroxidase (HRP) in the nanocage (1C) (Photo courtesy of Sissel Juul).
Initial phases of research have been started towards developing a nanorobot that in the long run will enable the targeted transport of pharmaceutical agents in the body.

In collaboration with American and Italian colleagues, researchers from Aarhus University (Aarhus, Denmark) have now taken a major move towards developing a nanorobot that will enable the targeted transport of medications in the body.

A nanorobot is a trendy term for molecules with a unique feature that enables them to be programmed to perform a specific task. In collaboration with colleagues in Italy and the United States, researchers at Aarhus University have now taken a major step towards building the first nanorobot of DNA molecules that can encapsulate and release active biomolecules.

The nanorobot (also known as a DNA nanocage) will eventually be used to transport drugs throughout the body and thereby have a targeted effect on diseased cells. Using DNA self-assembly, the researchers designed eight unique DNA molecules from the body’s own natural molecules. When these molecules are combined, they spontaneously aggregate in a usable form, the nanocage.

The nanocage has four functional components that transform themselves in response to changes in the surrounding temperature. These transformations either close or open the nanocage. By exploiting the temperature alterations in the environment, the researchers encapsulated an active enzyme called horseradish peroxidase (HRP) in the nanocage. They used HRP as a model because its activity is easy to trace.

This is possible because the nanocage’s outer lattice has apertures with a smaller diameter than the central spherical cavity. This structure makes it possible to encapsulate enzymes or other molecules that are larger than the apertures in the lattice, but smaller than the central cavity.

The researchers published their findings November 26, 2013, in the journal ACS Nano. The researchers demonstrated in their article how they could exploit temperature changes to open the nanocage and allow HRP to be encapsulated before it closes again. They also show that HRP retains its enzyme activity inside the nanocage and converts substrate molecules that are small enough to penetrate the nanocage to products inside.

The encapsulation of HRP in the nanocage is reversible, in such a way that the nanocage is capable of releasing the HRP once more in reaction to temperature changes. The researchers also show that the DNA nanocage with its enzyme load can be taken up by cells in culture. Looking towards the future, the idea behind this nanocage is expected to be used for drug delivery, i.e., as a means of transport for medicine that can target diseased cells in the body in order to achieve a more rapid and more beneficial effect.

The research was performed at the department of molecular biology and genetics and the Interdisciplinary Nanoscience Centre (iNANO) at Aaruhus, Aarhus University, in collaboration with researchers from Duke University (Durham, NC, USA) and the University of Rome (Italy).

Related Links:

Aarhus University
Duke University 
University of Rome



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.